Journal of Cutaneous Pathology · 1997 · 19 citations · 20 references
MedicineDermatologyPathologyHistopathologyNeoplasiaOncogenesImmunohistochemistryMelanocytic LesionsMelanocytic TumorsTumor DifferentiationTumor HistopathologyTumor MarkersMalignant Melanocytic LesionsMalignant Melanocytic TumorsMelanocytic Neoplasm PathologyMelanocytic Nevus HistopathologyMelanocytic Tumor HistopathologyMelanocytic Tumor ImmunohistochemistryMelanocytic Tumor Molecular PathologyMelanoma Histopathology
The expression of c-myc protein was studied in formalin-fixed, paraffin-embedded sections of 16 compound Spitz nevi (SNs), 20 ordinary compound melanocytic nevi (MNs) and 30 malignant melanomas (MMs), using monoclonal antibody 9E10 and an immunoperoxidase technique. Nine (56%) SNs, 16 (80%) MNs and 23 (77%) MMs showed positive reactions in some of the tumor cells (P = non-significant). The staining reactions were mostly cytoplasmic, and moderate to strong in intensity. The frequencies of positively stained cells were higher in the MN and SN groups. Most of the lesions with a significant dermal component did not show stratification of staining with progressive descent into the dermis. Therefore, the mode of expression of c-myc in routinely processed specimens does not differentiate between SNs, MNs and MMs. One possible reason is that the increased expression of the c-myc protein is not sufficient alone to promote proliferation and malignant transformation in these types of tumors.
20
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Toshiyuki Miyashita, Stanisław Krajewski, Maryla Krajewska et al. · PubMed · 1994 · 2.2K citations
Apoptotic cell death induced by c-myc is inhibited by bcl-2
Reid P. Bissonnette, Fernando Echeverri, Artin Mahboubi et al. · Nature · 1992 · 977 citations